Olmesartan

This MedLibrary.org supplementary page on Olmesartan is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:

Olmesartan
Systematic (IUPAC) name
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-(2-hydroxypropan-2-yl)-2-propyl-3-[ [4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate
Identifiers
CAS number 144689-63-4
ATC code C09CA08
PubChem 130881
DrugBank APRD00223
Chemical data
Formula C29H30N6O6 
Mol. mass 558.585 g/mol
SMILES eMolecules & PubChem
Pharmacokinetic data
Bioavailability 26% (olmesartan medoxomil)
Metabolism Hepatic (cannot be removed by hemodialysis)
Half life 13 hours
Excretion Renal 40%, biliary 60%
Therapeutic considerations
Pregnancy cat.

C (D if used in second or third trimester)

Legal status

Prescription only

Routes Oral

Olmesartan (Benicar,Olmetec) belongs to the class of medicines called angiotensin II receptor antagonists to treat high blood pressure. It is marketed worldwide by Daiichi Sankyo, Ltd. and in the United States by Daiichi Sankyo, Inc. and Forest Laboratories. Olmesartan works by blocking the binding of angiotensin II to the AT1 receptors in vascular muscle; it is therefore independent of angiotensin II synthesis pathways, unlike ACE inhibitors. By blocking binding rather than synthesis of angiotensin II, olmesartan inhibits the negative regulatory feedback on renin secretion. As a result of this blockage, olmesartan restricts vasoconstriction and the secretion of aldosterone. This lowers blood pressure by producing vasodilation, and decreasing peripheral resistance.Olmesartan also has high affinity for the Vitamin D Receptor[1] and because of the role of the Vitamin D receptor in innate immunity[2], olmesartan has immune modulatory properties.

Contents

Administration

Olmesartan is available in 5, 20, and 40 mg tablets. A normal dose for an adult (including the elderly and mild renal or hepatic impairment) is 20 mg/day in one dosage. This may be increased after two weeks to 40 mg/day if further blood pressure reduction is needed.

Myocardial infarction

A recent meta-analysis published in the peer-reviewed journal Circulation demonstrated that angiotensin II receptor antagonist induce myocardial infarction compared to placebo.[3]

Side effects

Side effects include:

Notes

^1. Website of National Institute of Heath, US Government. http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a603006.html#side-effects

^2. Website of Daiichi Sankyo, Inc. Goto: http://www.benicar.com/prod_info/index.asp?ref=1001011101 and open .pdf files containing product information Benicar and Benicar HCT

References

  1. ^ http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=16403216
  2. ^ http://www.ncbi.nlm.nih.gov/pubmed/16497887?ordinalpos=17&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum - [PubMed]
  3. ^ Strauss MH, Hall AS. (2006). "Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox.". Circulation 8 (114): 838–54. doi:10.1161/CIRCULATIONAHA.105.594986. PMID 16923768. 

Hodgson, Barbara B., and Kizior, Robert J. Saunders Nursing Drug Handbook 2006. St. Louis, MO: Elsevier, Saunders, 2006.

External links

Wikipedia content modification information:

  • This page was last modified on 1 July 2008, at 20:22.

Wikipedia Authorship and Review

Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.

Wikipedia Usage Guidelines

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Olmesartan".

The URL for this specific entry is:

All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.